#United States #Amgen #Thousand Oaks #Cardiovascular #Repatha

New Findings from AHA 2026

Amgen's presentation at the American Heart Association Scientific Sessions 2026 brought forth pivotal new data emphasizing the advantages of utilizing Repatha® (evolocumab) earlier in the spectrum of cardiovascular risk management. This newly released information strengthens the argument for more proactive approaches to lowering low-density lipoprotein cholesterol (LDL-C), particularly among those categorized as high-risk patients.

Importance of Early Intervention

The latest findings indicate that Repatha is not only effective but also cost-efficient for high-risk individuals who have not yet experienced a heart attack or stroke. The independent health economic analysis that delved into the data collected from the Phase 3 VESALIUS-CV trial assessed treatment costs against projected health benefits, concluding that Repatha performed approximately 36% below established ACC/AHA benchmarks for cost-effectiveness. Such statistics underscore the necessity of beginning treatment before any major cardiovascular incidents occur.

Murdo Gordon, Amgen's executive vice president of Global Markets and Policy, stressed the urgency of taking assertive measures against cardiovascular risks, given that heart attacks occur every 40 seconds in the U.S., with three-quarters being first-time events. According to Gordon, aligning robust clinical evidence with a commitment to overcome healthcare access barriers can facilitate faster achievement of optimal LDL-C levels—a critical goal for high-risk patients.

Comprehensive Evidence on Repatha's Effectiveness

In addition to cost-effectiveness, Amgen shared multiple analyses that illuminate Repatha’s benefits in varied patient populations, including those with chronic kidney disease (CKD). For example, data indicated that patients with CKD who had not experienced prior cardiovascular events faced an elevated cardiovascular risk, being 90% more likely to suffer coronary artery-related death or major cardiovascular events.

Over an average follow-up period of 4.6 years, treatment with Repatha significantly mitigated these risks, demonstrating a 39% reduction in major adverse cardiovascular events (MACE) rates and a 29% decline in all-cause mortality. The implications suggest that managing high LDL-C is crucial in reducing cardiovascular risks for patients with CKD, a fact emphasized in the newly released 2026 AHA/ACC/ADA/ASN guidelines.

Long-Term Benefits of Repatha

The effectiveness of Repatha in lowering LDL-C translates to substantial long-term cardiovascular benefit. A separate analysis determined that those treated with Repatha in the FOURIER study demonstrated a remarkable 29% lower rate of MACE after an extended duration, implying that the advantages of Repatha extend far beyond the period of clinical trials.

Repatha and Cardiovascular Disease: A Larger Commitment

Amgen's ongoing commitment to combat cardiovascular diseases positions the company as a leader in LDL-C management, driving innovations aimed at comprehensive care. The establishment of strategic partnerships and continual research efforts reflect a dedication not only to discovering new treatments but also ensuring that all patients have access to existing therapies, particularly those struggling with affordability issues.

Through initiatives like AmgenNow™, the company has actively worked to reduce the monthly cost of Repatha, making it more accessible to a broader patient population. With insurance coverage rates for Repatha soaring to around 96%, the steps taken to enhance affordability justify the investment in such a pivotal treatment option.

Conclusion

The findings presented at AHA 2026 illustrate the transformative potential of early treatment with Repatha in managing cardiovascular risk. The studies affirm that proactive measures in lowering LDL-C can significantly diminish the likelihood of heart attacks and other cardiovascular events, thus reiterating the importance of timely interventions for high-risk patients. As Amgen continues to lead the charge against cardiovascular diseases through innovation and accessibility, the future looks promising for improving patient outcomes in this critical healthcare area.